Avalon GloboCare Corp. announced that the Company has signed a memorandum of understanding with Lu Daopei Hematology Institute to co-develop precision companion diagnostics (CDx) for chimeric antigen receptor (CAR)-T cell therapies. To further strengthen its CDx development capabilities, Avalon has appointed Dr. Hongxing Liu, M.D., M.S., Executive President of LDHI and a world-renowned expert in precision diagnostics for hematologic malignancies, to its Scientific and Clinical Advisory Board.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4601 USD | -3.14% | +4.81% | -4.74% |
1st Jan change | Capi. | |
---|---|---|
-4.74% | 5.27M | |
-17.80% | 8.38B | |
+66.15% | 4.29B | |
+6.60% | 2.73B | |
-1.93% | 2.62B | |
-53.68% | 1.85B | |
-18.48% | 1.7B | |
-18.29% | 1.43B | |
+15.80% | 1.19B | |
-47.67% | 1.06B |
- Stock Market
- Equities
- ALBT Stock
- News Avalon GloboCare Corp.
- Avalon GloboCare Corp. Appoints Hongxing Liu to Scientific and Clinical Advisory Board